Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer

  • Authors:
    • Liying Guo
    • Qianwen Zhu
    • Mulati Aisimutuola
    • Dilimina Yilamu
    • Sha Liu
    • Adina Jakulin
  • View Affiliations

  • Published online on: March 23, 2015     https://doi.org/10.3892/etm.2015.2380
  • Pages: 2147-2150
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the expression of estrogen receptor β (ERβ) in triple‑negative and triple‑positive breast cancer patients, and evaluate its utility as a prognostic factor. Between January 2000 and December 2010, primary tumor tissue samples were collected from 234 subjects, including 107 triple‑negative and 127 triple‑positive breast cancer patients. The samples were embedded in paraffin and immunohistochemical staining was conducted to determine the expression levels of ERβ. The Kaplan‑Meier method was used to analyze patient survival rates. ERβ expression was observed in 38/107 patients (35.5%) with triple‑negative breast cancer and 63/127 patients (49.6%) with triple‑positive breast cancer. The ERβ expression rate was significantly decreased in the patients with triple‑negative breast cancer, as compared with those with triple‑positive breast cancer (P=0.03). Analysis of the survival rates indicated that patients with triple‑negative breast cancer and positive ERβ expression exhibited poor disease progression‑free survival (DFS) compared with those with negative ERβ expression (P=0.021). However, no statistically significant difference was observed in the DFS between the triple‑positive breast cancer patients with positive and negative ERβ expression. Therefore, the expression of ERβ varies between triple‑negative and triple‑positive breast cancer patients. In addition, positive expression of ERβ indicates a poor prognosis in triple‑negative breast cancer patients; however, this is not the case for triple‑positive breast cancer patients.
View Figures
View References

Related Articles

Journal Cover

June-2015
Volume 9 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo L, Zhu Q, Aisimutuola M, Yilamu D, Liu S and Jakulin A: Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer. Exp Ther Med 9: 2147-2150, 2015
APA
Guo, L., Zhu, Q., Aisimutuola, M., Yilamu, D., Liu, S., & Jakulin, A. (2015). Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer. Experimental and Therapeutic Medicine, 9, 2147-2150. https://doi.org/10.3892/etm.2015.2380
MLA
Guo, L., Zhu, Q., Aisimutuola, M., Yilamu, D., Liu, S., Jakulin, A."Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer". Experimental and Therapeutic Medicine 9.6 (2015): 2147-2150.
Chicago
Guo, L., Zhu, Q., Aisimutuola, M., Yilamu, D., Liu, S., Jakulin, A."Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer". Experimental and Therapeutic Medicine 9, no. 6 (2015): 2147-2150. https://doi.org/10.3892/etm.2015.2380